Company Overview and News
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
2018-07-19 seekingalpha - 2
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA GIS XOM IDCC SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP HP ORI SPG WPC ADM
Top 10 Financial Services "safer" dividend stocks, by broker one-year targets, averaged 14.4% in predicted one-year net as of 6/22/18.
AIY AINV MVC APO APAM AAALY MVCD MVCB AZIHF TCRX WBC MSB WEBNF AZIHY AIB WBK TCRD TCRZ TSLF OCSI WBC AAALF SLFPY
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG DUKH GD TRV MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
This is the seventh month I have officially tracked the taxable account's dividend income, and it was slightly below expectations with a total of $1,642.46 of dividends received.
SOJA GIS EBGUF XOM IDCC SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR EEP SO TLP WLK O MSB CMI WLKP ENB ETP HP PEP ORI SPG WPC ADM
Cliffs pellet contracts have historically given customers a steep discount to the world spot price of iron ore, which in turn reduced Mesabi's royalty distribution to trust unitholders.
VALE MSB CLF
This is the second month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $1,300.03.
ENB OPRF STI-A ABBV POL DUKH GD MAIN CMI ENB STI RY BNS JNJ GPT SPG WPC ABBV MSFT PFE PFBC CTL TD ETN BNS MSCA INTC TD IBM RY TNTTF O MSB DUK SNX MSCA.CL EMRAF ORI PPL DLR CBL
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.
SOJA GIS HTD XOM IDCC LTC OPRF BPL SEP MIC CINF ECC AAPL ECCZ CAH ECCY WASH SO GD TLP WLK O MSB PDT CMI ECCB ETP ECCA ORI SPG WPC
23h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
23h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET